In the present study, we report for the first time that caffeine mitigates experimental NASH by inhibiting NLRP3 inflammasome activation and decreasing the TLR4/MAPK/NF-κB pathway. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.